Bridgewise.vc’s Post

What could $73M in funding mean for the future of protein design and biotech innovation? Exciting times are ahead in the biotech sector as Cradle, a pioneering company focused on AI-driven protein design, has successfully raised an impressive $73 million to enhance its labs and expand its talented team. This substantial investment comes on the heels of growing recognition that leveraging AI technology is not just beneficial but essential for accelerating research and development processes in biotechnology. As more companies navigate complex biological challenges, Cradle’s advanced platform could be a game-changer. The infusion of funds will allow them to streamline their operations and innovate at unprecedented speeds. This raises intriguing questions about how rapidly evolving technologies will reshape our understanding of proteins — the building blocks of life! With corporate investments pouring into startups like Cradle who are committed to integrating AI with lab-based science then what does this mean for your industry? Will we soon see breakthroughs that can help address global health issues or improve sustainable practices? Join us in exploring the intersection of artificial intelligence and biotechnology! Share your thoughts below ⬇️ 💡 Connect with startups to drive your corporate innovation 🚀 Book a meeting! https://lnkd.in/dFYwmbHq #Biotech #AI #ProteinDesign #Innovation #Funding #Startups #TechNews #CradleAI #LifeSciences #CorporateInnovation Read more here: https://lnkd.in/dRFpxjmh

What could $73M in funding mean for the future of protein design and biotech innovation? Exciting times are ahead in the biotech sector as Cradle, a pioneering company focused on AI-driven protein design, has successfully raised an impressive $73 million to enhance its labs and expand its talented team. This substantial investment comes on the heels of growing recognition that leveraging AI technology is not just beneficial but essential for accelerating research and development processes in biotechnology. As more companies navigate complex biological challenges, Cradle’s advanced platform could be a game-changer. The infusion of funds will allow them to streamline their operations and innovate at unprecedented speeds. This raises intriguing questions about how rapidly evolving technologies will reshape our understanding of proteins — the building blocks of life! With corporate investments pouring into startups like Cradle who are committed to integrating AI with lab-based science then what does this mean for your industry? Will we soon see breakthroughs that can help address global health issues or improve sustainable practices? Join us in exploring the intersection of artificial intelligence and biotechnology! Share your thoughts below ⬇️ 💡 Connect with startups to drive your corporate innovation 🚀 Book a meeting! https://lnkd.in/dFYwmbHq #Biotech #AI #ProteinDesign #Innovation #Funding #Startups #TechNews #CradleAI #LifeSciences #CorporateInnovation Read more here: https://lnkd.in/dRFpxjmh

What could $73M in funding mean for the future of protein design and biotech innovation? Exciting times are ahead in the biotech sector as Cradle, a pioneering company focused on AI-driven protein design, has successfully raised an impressive $73 million to enhance its labs and expand its talented team. This substantial investment comes on the heels of growing recognition that leveraging AI technology is not just beneficial but essential for accelerating research and development processes in biotechnology. As more companies navigate complex biological challenges, Cradle’s advanced platform could be a game-changer. The infusion of funds will allow them to streamline their operations and innovate at unprecedented speeds. This raises intriguing questions about how rapidly evolving technologies will reshape our understanding of proteins — the building blocks of life! With corporate investments pouring into startups like Cradle who are committed to integrating AI with lab-based science then what does this mean for your industry? Will we soon see breakthroughs that can help address global health issues or improve sustainable practices? Join us in exploring the intersection of artificial intelligence and biotechnology! Share your thoughts below ⬇️ 💡 Connect with startups to drive your corporate innovation 🚀 Book a meeting! https://lnkd.in/dFYwmbHq #Biotech #AI #ProteinDesign #Innovation #Funding #Startups #TechNews #CradleAI #LifeSciences #CorporateInnovation Read more here: https://lnkd.in/dRFpxjmh

What could $73M in funding mean for the future of protein design and biotech innovation? Exciting times are ahead in the biotech sector as Cradle, a pioneering company focused on AI-driven protein design, has successfully raised an impressive $73 million to enhance its labs and expand its talented team. This substantial investment comes on the heels of growing recognition that leveraging AI technology is not just beneficial but essential for accelerating research and development processes in biotechnology. As more companies navigate complex biological challenges, Cradle’s advanced platform could be a game-changer. The infusion of funds will allow them to streamline their operations and innovate at unprecedented speeds. This raises intriguing questions about how rapidly evolving technologies will reshape our understanding of proteins — the building blocks of life! With corporate investments pouring into startups like Cradle who are committed to integrating AI with lab-based science then what does this mean for your industry? Will we soon see breakthroughs that can help address global health issues or improve sustainable practices? Join us in exploring the intersection of artificial intelligence and biotechnology! Share your thoughts below ⬇️ 💡 Connect with startups to drive your corporate innovation 🚀 Book a meeting! https://lnkd.in/dFYwmbHq #Biotech #AI #ProteinDesign #Innovation #Funding #Startups #TechNews #CradleAI #LifeSciences #CorporateInnovation Read more here: https://lnkd.in/dRFpxjmh

What could $73M in funding mean for the future of protein design and biotech innovation? Exciting times are ahead in the biotech sector as Cradle, a pioneering company focused on AI-driven protein design, has successfully raised an impressive $73 million to enhance its labs and expand its talented team. This substantial investment comes on the heels of growing recognition that leveraging AI technology is not just beneficial but essential for accelerating research and development processes in biotechnology. As more companies navigate complex biological challenges, Cradle’s advanced platform could be a game-changer. The infusion of funds will allow them to streamline their operations and innovate at unprecedented speeds. This raises intriguing questions about how rapidly evolving technologies will reshape our understanding of proteins — the building blocks of life! With corporate investments pouring into startups like Cradle who are committed to integrating AI with lab-based science then what does this mean for your industry? Will we soon see breakthroughs that can help address global health issues or improve sustainable practices? Join us in exploring the intersection of artificial intelligence and biotechnology! Share your thoughts below ⬇️ 💡 Connect with startups to drive your corporate innovation 🚀 Book a meeting! https://lnkd.in/dTxGsKrN #Biotech #AI #ProteinDesign #Innovation #Funding #Startups #TechNews #CradleAI #LifeSciences #CorporateInnovation Read more here: https://lnkd.in/dqUEeaBb

In these past 3 weeks I appeared before 8 different groups of professionals from academia, industry, innovation & entrepreneurship, in various sizes and forums. I spoke about the National Bio-convergence Program and discussed where and how the program and field may meet and affect them. I was thrilled to meet hundreds of people fascinated by the great potential, complexity and promise that bio-convergence has for them and the for the whole world - in bio-chips/devices, AI4bio, bio-manufacturing, SynBio, precision Ag/Med/Dx/Rx, green energy, carbon uptake, bio-remediation and SO MUCH MORE ! Where does bio-convergence meet YOU? Is there bio-convergence in YOUR R&D and/or business? Are you part of a multi-disciplinary team converging Biology with other technologies? If so - tell us about it! Comment here, email me, call, text or... Join our new Bio-convergence group! https://lnkd.in/dGCFsW9Y Israel Innovation Authority רשות החדשנות Be part of the bio-convergence community - share experiences, goals, aspirations, queries, challenges, suggestions and thoughts in general. #bioconvergence #Israelinnovationauthority #community #tech #startup #biotech #agtech #foodtech #biomed #ai #entrepreneurship

Title: Leveraging Automation: A Game-Changer for Life Science Startups As the life science industry continues to evolve and innovate at a rapid pace, startups in this space face unique challenges and opportunities. From drug discovery to biotech research, the demand for efficiency, accuracy, and scalability is higher than ever before. In this dynamic landscape, automation emerges as a powerful ally, offering numerous advantages to life science startups. Let’s explore why integrating automation into operations is not just beneficial but essential for the success and growth of these ventures. 1. Speeding Up Research and Development: Automation frees up researchers' time from repetitive tasks, accelerating the pace of discovery and development. 2. Ensuring Accuracy and Consistency: Automated processes reduce the margin for error, ensuring reliable and reproducible results vital for scientific integrity. 3. Optimizing Costs and Resources: Startups can maximize efficiency and minimize waste, making every dollar count towards progress. 4. Scaling Operations Seamlessly: Automation provides the flexibility to scale operations smoothly as startups grow, without sacrificing quality. 5. Meeting Regulatory Standards: Automated systems help ensure compliance with strict regulatory requirements, simplifying audits and inspections. In conclusion, automation holds immense potential to revolutionize the way life science startups operate and innovate. By embracing automation technologies, these ventures can achieve greater efficiency, accuracy, and scalability while driving down costs and accelerating time-to-market. As the life science landscape continues to evolve, integrating automation into operations will not only be a competitive advantage but a necessity for success in this dynamic and demanding industry. Therefore, at @Cellcolab we provide several options to automate research workflows e.g. capillary based western blotting, automated Elisa, DNA/RNA extraction and liquid handling from nanoliter to µL range. Let us know what you think about automation for life science startups in the comments. #biotech #startup #entrepreneurship #biotechnology #coworking #incubator #lifescience #laboratory

In the "Century of Biology," biotech startups stand on the brink of unparalleled discoveries and innovations. At Adelphi Ventures, we recognize that the journey to secure crucial funding extends beyond mere milestones. It demands agility, foresight, and the strategic integration of cutting-edge technologies like AI and high-throughput techniques. As the race against time and competition intensifies, embracing these technologies early can significantly enhance a startup's appeal to investors, ensuring not just survival, but a robust path to commercialization. Let's champion the biotech innovators prepared for tomorrow, today. 🚀 Reference: How automation can help biotech startups - News-Medical.Net https://lnkd.in/es7BbSAs #BiotechInnovation #NextGenTech #FundingReadiness #AIinBiotech #Commercialization #StartupGrowth #TechAdoption #FutureOfBiotech #InvestInBiotech #AdelphiVentures

🚀 Transforming Research into Innovation! 🌟  Join us on 6 December 2024 for an inspiring discussion panel featuring leaders from the worlds of biotechnology and AI startups! These trailblazers have successfully bridged the gap between academia and entrepreneurship, turning groundbreaking research into industry-changing innovations. 🧬🤖  🎙️ Our panelists:   1️⃣ Hugo Saavedra – CEO, Kyan Technologies   2️⃣ Samantha Wong, PhD – Director & External Partnerships, Nucleate Singapore   3️⃣ Too Heng-Phon – Cofounder & Chief Scientific Advisor, Mirxes   4️⃣ Torsten Wuestefeld – Cofounder & Advisor, Lerna Biopharma   5️⃣ Harshyaa Makhija – Cofounder & Director, LambdaGen Pte Ltd  ✨ Moderator: Dr. Ashwati Vipin, PhD, LKCMedicine  Get ready for insights on:   💡 The entrepreneurial mindset   💡 Commercializing research   💡 Opportunities for researchers in biotech & AI  Don’t miss this chance to learn from their journeys and strategies! 🌟  #Biotech #AI #Entrepreneurship #Innovation #ResearchToStartups #BiotechStartups #ENABLE2024

👉 𝐐𝐮𝐢𝐜𝐤 𝐁𝐲𝐭𝐞𝐬: New Wave Biotech, a London-based AI-driven bioprocess simulation startup, has secured €1.2 million in funding from EIT Food and Innovate UK. Founded in 2022 by Zoe Yu Tung Law and Oli Hall, the company aims to revolutionize biomanufacturing by enhancing the design, commercialization, and scalability of sustainable production processes. Their Bioprocess Foresight platform utilizes AI to simulate bioprocesses, predicting outputs, costs, and sustainability impacts, thereby accelerating the transition from lab to market. This investment will support New Wave Biotech in expanding its team, advancing technology, and broadening its customer base. #Biotech #AI #SustainableManufacturing #Innovation #Funding #Bioprocessing #SyntheticBiology #AlternativeProteins #TechNews #StartupGrowth